Geographic Atrophy Secondary to Age-related Macular Degeneration

Ophthalmology
6
Pipeline Programs
2
Companies
4
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
2
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Apellis Pharmaceuticals
EMPAVELIApproved
pegcetacoplan
Apellis Pharmaceuticals
Complement Inhibitor [EPC]subcutaneous2021
Apellis Pharmaceuticals
SYFOVREApproved
pegcetacoplan
Apellis Pharmaceuticals
Complement Inhibitor [EPC]intravitreal2023

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Apellis Pharmaceuticals
Apellis PharmaceuticalsAustralia - Hawthorn East
3 programs
1
2
1
APL-2, PegcetacoplanPhase 31 trial
PEGCETACOPLANPhase 31 trial
APL-3007, pegcetacoplanPhase 21 trial
Active Trials
NCT07215390Recruiting240Est. Nov 2027
NCT07214740Completed44Est. Dec 2025
NCT04770545Completed792Est. Sep 2025
Kriya Therapeutics
Kriya TherapeuticsCA - Redwood City
1 program
1
VV-14295Phase 1/21 trial
Active Trials
NCT06765980RecruitingEst. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Apellis PharmaceuticalsAPL-2, Pegcetacoplan
Apellis PharmaceuticalsPEGCETACOPLAN
Apellis PharmaceuticalsAPL-3007, pegcetacoplan
Kriya TherapeuticsVV-14295

Clinical Trials (4)

Total enrollment: 1,076 patients across 4 trials

NCT07214740Apellis PharmaceuticalsAPL-2, Pegcetacoplan

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

Start: Oct 2025Est. completion: Dec 202544 patients
Phase 3Completed
NCT04770545Apellis PharmaceuticalsPEGCETACOPLAN

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

Start: Mar 2021Est. completion: Sep 2025792 patients
Phase 3Completed
NCT07215390Apellis PharmaceuticalsAPL-3007, pegcetacoplan

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Start: Jun 2025Est. completion: Nov 2027240 patients
Phase 2Recruiting
NCT06765980Kriya TherapeuticsVV-14295

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Start: May 2025Est. completion: Dec 2027
Phase 1/2Recruiting

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
8h ago

Cleanroom and Laboratory Technician

SAB BIO
9h ago

Material Handler - 8 Hour Day Shift

Pfizer
United States - Kansas - McPherson
Yesterday

Senior Process Technician - Rotating 2nd Shift

Pfizer
United States - Massachusetts - Andover
Yesterday
$27 - $45/hr

Staff Equipment and Systems Engineer

Johnson & Johnson
Plymouth, Minnesota, United States of America
Yesterday
$94K - $152K/yr

APAC Regulatory Affairs Manager

Johnson & Johnson
Singapore, Singapore
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,076 patients
2 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)